SLC5A2 and chronic kidney disease: Actuarial analyses using data from large-scale clinical studies showed that, compared with RAS inhibitor monotherapy, the use of a combination of RAS inhibitor with one, two or all three of the following — a SGLT2 inhibitor, a nsMRA, or a GLP-1R inhibitor — progressively suppresses the incidence of hospitalization for heart failure and CKD events27).